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Abstract 
Chronic Granulomatous Disease (CGD) is an inherited primary immunodeficiency disorder 
with an incidence of ~ 1:200,000 live births. This disease is caused by mutations in the 
NAPDH oxidase, the phagocytic enzyme responsible for pathogen killing. As a result, CGD 
patients suffer from recurrent bacterial and fungal infections and often life threatening 
inflammatory complications. Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) 
remains the only proven curative treatment for patients with CGD. The use of reduced 
intensity conditioning regimens (to limit toxicity) and the extended use of HLA-matched or 
single antigen mismatched unrelated grafts can now achieve excellent donor myeloid 
chimerism and >90% overall survival rate. However, it is not always possible to find a 
suitable donor and autologous gene therapy has become an attractive alternative option. A 
phase I/II clinical trial of lentiviral gene therapy is currently underway for X-linked CGD, the 
most common form of the disease. We propose to use a similar strategy to tackle p47phox 
deficient CGD, caused by mutations in the NCF1 gene encoding the cytosolic p47phox subunit 
of the NADPH oxidase. p47phox deficient CGD is the most common form of autosomal 
recessive CGD and accounts for approximately 25-30% of patients in the Western world (this 
is likely to be higher in some consanguineous populations worldwide). We have developed 
and tested a self-inactivating lentiviral vector containing a codon-optimized p47phox transgene 
under the transcriptional control of the chimeric cathepsin G/c-fes myeloid promoter 
(pCCLChim-p47). When used in a p47phox deficient myeloid cell line and in monocyte-
derived macrophages from p47phox CGD patients, the lentiviral vector was able to restore 
p47phox expression and oxidase activity to normal levels. In a murine model of stem cell gene 
therapy for p47phox deficient CGD, the pCCLChim-p47 vector induced high expression of the 
p47phox protein in granulocytes from blood and bone marrow of gene therapy treated mice and 
restored levels of NADPH-oxidase activity that were comparable to those found in wt 
animals (with an average of~ 1 vector copy per cell). As expected, the expression of the 
p47phox protein was mainly confined to myeloid cells in blood, bone marrow and spleen. The 
percentage of functional neutrophils remained stable over time up to six months, suggesting 
that the vector is not prone to epigenetic inactivation. The presence of corrected granulocytes 
in secondary transplanted animals also indicates that we can successfully transduce 
haematopoietic stem cells. Overall this study shows that the pCCLChim-p47 vector is a 
promising tool for the clinical gene therapy of p47phox deficient CGD. 
 
